Key Strengths Strong revenue growth (+250% in 2015e) from internal, partnered and acquired products (expecting guidance to be raised at 3Q15 conf call) Increasing margins (approaching 70% on internal products) reflects the continued shift away from historic contract mfr business Improved balance sheet (recently raised ~$30M at $4.55) Partner Validation (Celgene has a 15% equity position and both their CMO and Head of CELG Cellular therapeutics sit on the BoD)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.